Protective Polymer Coatings (PPCs) have been proposed to protect lithium metal anodes in rechargeable batteries to stabilize the Li/electrolyte interface and to extend the cycle life by reducing parasitic reactions and improving the lithium deposition morphology. However, the ion transport mechanism in PPCs remains unclear. Specifically, the degree of polymer swelling in the electrolyte and the influence of polymer/solvent/ion interactions are never quantified. Here we use poly(acrylonitrile-co-butadiene) (PAN-PBD) with controlled cross-link densities to quantify how the swelling ratio of the PPC affects conductivity, Li⁺ ion selectivity, activation energy, and rheological properties. The large difference in polarities between PAN (polar) and PBD (non-polar) segments allows the comparison of PPC properties when swollen in carbonate (high polarity) and ether (low polarity) electrolytes, which are the two most common classes of electrolytes. We find that a low swelling ratio of the PPC increases the transference number of Li⁺ ions while decreasing the conductivity. The activation energy only increases when the PPC is swollen in the carbonate electrolyte because of the strong ion-dipole interaction in the PAN phase, which is absent in the non-polar PBD phase. Theoretical models using Hansen solubility parameters and a percolation model have been shown to be effective in predicting the swelling behavior of PPCs in organic solvents and to estimate the conductivity. The trade-off between conductivity and the transference number is the primary challenge for PPCs. Our study provides general guidelines for PPC design, which favors the use of non-polar polymers with low polarity organic electrolytes.

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans. However, it has not yet been possible to induce adequate serological responses by vaccination. Here, to activate B cells that express precursors of broadly neutralizing antibodies within polyclonal repertoires, we developed an immunogen, RC1, that facilitates the recognition of the variable loop 3 (V3)-glycan patch on the envelope protein of HIV-1. RC1 conceals non-conserved immunodominant regions by the addition of glycans and/or multimerization on virus-like particles. Immunization of mice, rabbits and rhesus macaques with RC1 elicited serological responses that targeted the V3-glycan patch. Antibody cloning and cryo-electron microscopy structures of antibody-envelope complexes confirmed that immunization with RC1 expands clones of B cells that carry the anti-V3-glycan patch antibodies, which resemble precursors of human broadly neutralizing antibodies. Thus, RC1 may be a suitable priming immunogen for sequential vaccination strategies in the context of polyclonal repertoires.